本帖最后由 老马 于 2012-1-13 21:20 编辑
/ W. G+ j! d. r( w; H' M7 J1 C/ S2 K* d6 ?
爱必妥和阿瓦斯丁的比较
+ O! P- O, U7 H1 r0 l8 X( s* ]4 o
0 h# K q s2 ?0 V$ Y
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/% A! }; P) }7 k+ J3 a9 f8 `6 {
7 I. u% \5 W7 B/ @; y
* y/ z5 }7 l$ U9 d- o! X
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
" {6 o% z3 c4 Q==================================================7 M0 q: h/ d3 I0 u$ e, ^6 }$ G& V
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
/ J3 }7 n; S( uPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.4 u( ]4 D( u' ~' T
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.) @4 L3 k, p! m0 E; G3 ^3 h- z
|
显身卡
?) ?4 p% L) [) @. x# M: {* U
